Rachel Klemovitch, Assistant Editor06.25.24
Ixlayer, a healthcare technology platform that enables direct-to-patient solutions for biopharma companies, released the results of a new survey unveiling insights into provider’s attitudes towards at-home diagnostic testing in healthcare.
The survey was conducted by the DHC Group and Sermo, and polled over 140 physicians across multiple specialties nationwide.
The data showed that 83% of U.S. physicians believe at-home testing can help move patients through the care continuum faster, accelerating the path to diagnosis and improving health outcomes. 87% of physicians also acknowledged that at-home testing improves access to diagnostic services, citing benefits such as convenience and improved compliance.
"The sooner patients get diagnosed, the sooner they get connected with the care they need to stay healthy. This survey proves physicians are aligned in their support for at-home testing to help speed the patient journey and improve overall health outcomes," said ixlayer's Head of Clinical Innovation, Bernard Esquivel, MD, PhD.
"Given the robust support from physicians for at-home testing to facilitate quicker and more informed healthcare decisions, biopharma companies should seize this valuable opportunity to reach more patients, decrease time to diagnosis, and better support positive outcomes," said Matthew Walsh, General Manager, Biopharma at ixlayer.
Key findings include:
The survey was conducted by the DHC Group and Sermo, and polled over 140 physicians across multiple specialties nationwide.
The data showed that 83% of U.S. physicians believe at-home testing can help move patients through the care continuum faster, accelerating the path to diagnosis and improving health outcomes. 87% of physicians also acknowledged that at-home testing improves access to diagnostic services, citing benefits such as convenience and improved compliance.
"The sooner patients get diagnosed, the sooner they get connected with the care they need to stay healthy. This survey proves physicians are aligned in their support for at-home testing to help speed the patient journey and improve overall health outcomes," said ixlayer's Head of Clinical Innovation, Bernard Esquivel, MD, PhD.
"Given the robust support from physicians for at-home testing to facilitate quicker and more informed healthcare decisions, biopharma companies should seize this valuable opportunity to reach more patients, decrease time to diagnosis, and better support positive outcomes," said Matthew Walsh, General Manager, Biopharma at ixlayer.
Key findings include:
- 80% said at-home diagnostic testing would support or enhance current provider workflows.
- Two out of three believe at-home tests are reliable (63%) and trust (64%) the process of generating results.
- 91% reported they would provide at-home diagnostic kits to their patients.
- 84% of physicians felt it was important to have the results of at-home testing automatically routed to their office.